Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-11-20
2010-10-05
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S135100, C424S172100
Reexamination Certificate
active
07807166
ABSTRACT:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−−signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22 (LYM 22), sHIgm46 (LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.
REFERENCES:
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 2005/0282252 (2005-12-01), Siegel
patent: 2008/0233132 (2008-09-01), Miller et al.
patent: WO 92/04442 (1992-03-01), None
patent: WO 95/30004 (1995-11-01), None
Warrington et al. 2000 Proc Natl Acad Sci USA 97:6820-6825.
Ciric 2001 Blood 97:321-323.
UniProt P01072, accessed Apr. 1, 2010.
Abo et al., J. Immunol., 127 (1981), 1024-1029.
Asakura et al., J. Neuroscience Res. (1996) 43, pp. 273-281.
Asakura, K. et al, Mol Brain Res, (1995) 34:283-293.
Asakura, K., D.J. Miller, L.R. Pease, and M. RodriguezJournal of Neuroscience(1998) 18:7700-7708.
Asakura, K. et al. Neurology 54(7): A126-A127 (Supp 3) (2000).
Bansal et al, Proc Natl Acad Sci (1989) 86:6181-6185.
Bansal, R. et al., J. Neurosci. Res. (1988) 21:260-267.
Benjamins, J.A. and Dyer, C.A., Ann. NY Acad. Sci., 605:90-100 (1990).
Diaz, M. et al., Brain Res., 154:231-239 (1978).
Dyer, C.A., Mol. Neurobiol., 7:1-22 (1993).
Eisenbarth et al., Proc. Natl. Acad. Sci. USA, 76 (1979), 4913-4917.
Fredman et al., Arch. Biochem. Biophys., 233 (1984), 661-666.
Gard et al., Neuron, 5 (1990), 615-625.
Kasai et al., Brain Res., 277 (1983), 155-158.
Kirschning, E. et al. J. Immun (1999) 99(1):122-130.
Lehrer, G.M. et al., Brain Res., 172:557-560 (1979).
Miller et al., J. Neurosci., 14 (1994), 6230-6238.
Miller, D.J. and M. Rodriguez, J Immunol (1995) 154:2460-2469.
Miller, D.J. and Rodriguez, M., Microscopy Res & Tech (1995) 32:230-245.
Miller, D.J. et al, J Neurosci Res (1995) 41:291-296.
Miller, D.J. et al, J Neurosci (1995)1545:8345-8352.
Miller et al., International Immunology, (1996) 8, pp. 131-141.
Miller, D.J. et al, J Neuroimmunol (1997) 75:204-209.
Raine, C.S. and Wu, E.J., lab Invest (1978) 38(4):397-403.
Rodriguez M. et al, J Neuropathol Exp Neurol (1987) 46:84-95.
Rodriguez, et al., Ann. Neurol (1990) 27:12-17.
Rodriguez, M., J Neuroimmunol (1992) 40:255-264.
Rodriguez, M. and Lindsley, M.D., Neurology (1992) 42(2):348-357.
Rodriguez, M. and Miller, D.J., Prog Brain Res (1994) 103:343-355.
Schachner, J. Neurochem., 39 (1982), 1-8.
Schuller-Petrovic et al., Nature, 306 (1983), 179-181.
Sommer et al., Dev. Biol., 83 (1981), 311-327.
Miller David J.
Pease Larry R.
Rodriguez Moses
Kolker Daniel E.
Mayo Foundation for Medical Education and Research
LandOfFree
Methods of promoting remyelination of central nervous system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of promoting remyelination of central nervous system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of promoting remyelination of central nervous system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218502